“…The anti‐HIV‐1 IIIB SAR of 1,2,3‐triazole–pyrimidine hybrids 18 (Figure 4; EC 50 : 13–73 nM, the MTT [3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyl tetrazolium bromide] method using MT‐4 cells) and 19 (EC 50 : 56–5,620 nM) demonstrated that the linker between 1,2,3‐triazole and phenyl ring impacted the activity greatly, and the relative contribution order was as follows: without linker > methylene > ethylene > acetamide; the electron‐withdrawing group at the phenyl ring could enhance the activity. [ 59 ] The structure–cytotoxicity relationship revealed that extension of the carbon spacer between 1,2,3‐triazole and phenyl ring increased the cytotoxicity toward mock‐infected cells, and 1,2,3‐triazole–pyrimidine hybrids without linker exhibited the lowest cytotoxicity. The 1,2,3‐triazole–pyrimidine hybrids 18a , b (EC 50 : 20 and 13 nM) were not only comparable to AZT (EC 50 : 12 nM) against HIV‐1 IIIB , but they were also nontoxic toward mock‐infected cells (CC 50 : >241 µM), and the TI values were >11,830.…”